在心脏移植候选人中,TAPSE/PASP比率与运动能力之间的关联,这些人患有晚期心力衰竭
Rezzan Deniz Acar1, Murat Karacam2, Seda Tanyeri1
1Department of Cardiology, Kartal Kosuyolu Research and Education Hospital, Istanbul, Türkiye.
Frontiers in cardiovascular medicine
|February 6, 2026
概括
三环状平面缩外流到肺动脉缩压 (TAPSE/PASP) 的比率与等待心脏移植的高级心力衰竭患者的更好的运动能力和结果有关. 这种非侵入性标志物有助于对这些人进行风险分层.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 移植医学 移植医学
背景情况:
- 峰值氧气消耗 (VO2) 对于高级心力衰竭 (HF) 的心脏移植资格至关重要.
- 评估右心室 - 肺动脉 (RV-PA) 合对于理解HF预后至关重要.
研究的目的:
- 评估TAPSE/PASP比率与心脏移植候选人的运动能力 (峰值VO2) 之间的关联.
- 为了确定TAPSE/PASP比率的预后值在晚期HF患者.
主要方法:
- 对384名正在接受心脏移植评估的高级HF患者进行了回顾性分析.
- 使用心声回声,心肺运动测试 (CPET) 和右心脏导管 (RHC).
- 用多变量回归和考克斯的比例危险模型来评估关联.
主要成果:
- 更高的TAPSE/PASP比率与更好的运动持续时间,峰值VO2和呼吸器效率相关.
- TAPSE/PASP与VO2峰值 (效果大小:6.7;p < 0.001) 有着强烈的关联.
- 较高的TAPSE/PASP独立预测较低的死亡率,LVAD植入或移植 (aHR:0.78;p < 0.001).
结论:
- TAPSE/PASP比率是高级高压患者运动能力的重要预测指标.
- 这种非侵入性标志物可能会增强心脏移植候选人的风险分层和管理策略.
- 将TAPSE/PASP纳入移植方案可以改善患者选择和监测.
相关概念视频
01:29Heart Failure II: Pathophysiology
964
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
964
01:17Pathophysiology of Heart Failure
3.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
01:27Heart Failure I: Introduction
903
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
01:22Heart Failure VI: Adjunct Therapies
348
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
01:22Heart Failure Drugs: Diuretics
987
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
987
01:30Heart Failure V: Medical Management
330
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
330